Citation Tools
PDFRegular and Young Investigator Award Abstracts
Clinical Trial In Progress
632 A phase 1/2 open label study of LabVax 3(22)-23 and adjuvant GM-CSF alone or in combination with pembrolizumab in subjects with labyrinthin-positive adenocarcinomas
Download to a citation manager
Download the citation for this article by clicking on one of the following citation managers:
- Cite this article as:
- 632 A phase 1/2 open label study of LabVax 3(22)-23 and adjuvant GM-CSF alone or in combination with pembrolizumab in subjects with labyrinthin-positive adenocarcinomas